AZD8630/AMG 104, an inhaled Anti-TSLP antibody fragment, for moderate-to-severe asthma: a phase 1 randomized controlled trial

Journal:

The Journal of Allergy and Clinical Immunology

Published:

2026-04-20

DOI:

10.1016/j.jaci.2026.03.026

Affiliations:

17

Authors:

20

Go to article

Institutions	Authors	Share
AstraZeneca Sweden, Sweden	4.500000	0.23
Amgen, United States of America (USA)	4.000000	0.20
AstraZeneca, United Kingdom (UK)	4.000000	0.20
AstraZeneca Cambridge, United Kingdom (UK)	2.500000	0.13
AstraZeneca United States, United States of America (USA)	1.000000	0.05
Bradford Teaching Hospitals NHS Foundation Trust, United Kingdom (UK)	1.000000	0.05
Portsmouth Hospitals NHS Trust, United Kingdom (UK)	1.000000	0.05
Insaf Respiratory Research Institute, Germany	1.000000	0.05
University of Birmingham, United Kingdom (UK)	0.500000	0.03
Imperial College London (ICL), United Kingdom (UK)	0.500000	0.03

Interested in Immunology?